brimonidine tartrate; brinzolamide - Profile

What are the generic sources for brimonidine tartrate; brinzolamide and what is the scope of patent protection?

Brimonidine tartrate; brinzolamide is the generic ingredient in one branded drug marketed by Alcon Labs Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brimonidine tartrate; brinzolamide has fifty-one patent family members in twenty-six countries.

Summary for brimonidine tartrate; brinzolamide

International Patents:	51
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for brimonidine tartrate; brinzolamide

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for brimonidine tartrate; brinzolamide

Constraining patent/regulatory exclusivity:

9,044,484

Dosage:

SUSPENSION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SIMBRINZA	Ophthalmic Suspension	brimonidine tartrate; brinzolamide	1%/0.2%	204251	1	2022-08-01

US Patents and Regulatory Information for brimonidine tartrate; brinzolamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013		RX	Yes	Yes	9,044,484		Y
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013		RX	Yes	Yes	9,421,265		Y

Expired US Patents for brimonidine tartrate; brinzolamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013	6,316,441

EU/EMA Drug Approvals for brimonidine tartrate; brinzolamide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Simbrinza	brinzolamide, brimonidine tartrate	EMEA/H/C/003698Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.	Authorised	no	no	no	2014-07-18

International Patents for brimonidine tartrate; brinzolamide

Country	Patent Number	Title	Estimated Expiration
San Marino	T201600249	COMPOSIZIONI FARMACEUTICHE ACQUOSE CONTENENTI COMPLESSI BORATO- POLIOLO
Australia	2010262898
Chile	2010000634
Hong Kong	1163521

Supplementary Protection Certificates for brimonidine tartrate; brinzolamide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014C/042	Belgium		PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225

Investment Scenario, Market Dynamics, and Financial Trajectory for Brimonidine Tartrate and Brinzolamide

Last updated: February 3, 2026

Summary

This report analyzes the investment potential, market factors, and financial forecast of two notable ophthalmic drugs: Brimonidine Tartrate and Brinzolamide. These drugs are primarily used for glaucoma management. The analysis covers market size, growth drivers, competitive landscape, regulatory environment, revenue projections, and key risks, providing insights crucial for stakeholders considering investment or strategic positioning.

---

What Are Brimonidine Tartrate and Brinzolamide?

Brimonidine Tartrate and Brinzolamide are topical medications used predominantly in the treatment of glaucoma and ocular hypertension. They are often administered as eye drops, sometimes in fixed-dose combinations (FDCs).

Drug	Therapeutic Class	Mechanism of Action	Formulation	Primary Indications
Brimonidine Tartrate	Alpha-2 adrenergic receptor agonist	Reduces aqueous humor production and increases uveoscleral outflow	Ophthalmic solution	Glaucoma, ocular hypertension
Brinzolamide	Carbonic anhydrase inhibitor	Decreases aqueous humor production	Ophthalmic suspension	Glaucoma, ocular hypertension

---

Market Size and Growth Drivers (2023-2030)

Global Ophthalmic Drug Market

• Estimated worth $6.2 billion in 2022; projected to reach $8.4 billion by 2030, growing at a CAGR of 4.0% (Transparency Market Research, 2022).
• Glaucoma therapeutics comprise approximately 25–30% of the total ophthalmic market.

Market for Brimonidine Tartrate

• Market value (2022): Approx. $800 million globally.
• Forecast (2023–2030): Compound annual growth rate of 3–4%.
• Growth factors:
  • Aging population leading to increased glaucoma prevalence.
  • Rising awareness and early diagnosis.
  • Expansion in developing markets with increased healthcare infrastructure.

Market for Brinzolamide

• Market value (2022): Estimated at $600 million.
• Forecast (2023–2030): CAGR of 4–5%.
• Growth factors:
  • Preference for combination therapies reducing pill burden.
  • Favorable regulatory approvals in emerging markets.
  • Competitive edge via fixed-dose combinations and patent expiries.

---

Competitive Landscape and Key Players

Drug	Major Manufacturers	Market Share (2022)	Recent Approvals/Launches	Pipeline Status
Brimonidine Tartrate	Allergan (AbbVie), Santen, Bausch + Lomb	45–50%	Bimonidine (incremental improvements)	Several generics available
Brinzolamide	Alcon, Santen, Akorn	35–40%	Fixed-dose combinations with timolol, brimonidine	Emerging biosimilars

Note: Patent expiries between 2022-2025 are anticipated to increase generic competition.

Market Entry Barriers

• Regulatory approvals requiring extensive clinical data.
• Manufacturing complexities for ophthalmic solutions.
• Distribution constraints due to specialized storage conditions.

---

Regulatory Environment and Patent Landscape

Regulatory Pathways

• FDA and EMA approval processes, typically requiring clinical efficacy and safety data.
• Fast-track pathways available for orphan or breakthrough indications, primarily in emerging markets.

Patent Status

Patent Expiry (Approx.)	Implication	Observations
2023–2025	Increased generic entry	Significant price reductions anticipated
2026+	Potential for biosimilar development	Opportunities in biosimilars for combination therapies

Impact on Market Dynamics

Patent expiries are expected to:

• Lower average selling prices (ASPs).
• Augment market competition.
• Compel innovation in formulations and delivery mechanisms.

---

Financial Trajectory and Revenue Projections

Historical Revenue (2022)

Drug	Revenue (USD Million)	Growth Rate (2020–2022)
Brimonidine Tartrate	800	2.5% CAGR
Brinzolamide	600	3.0% CAGR

Projected Revenue (2023–2030)

Drug	2023	2025	2027	2030
Brimonidine Tartrate	860	940	1,020	1,200
Brinzolamide	630	700	780	900

Assumptions:

• Market growth aligns with CAGR estimates.
• Launch of combination drugs enhances market share.
• Patent expiries influence pricing and volume.

Key Revenue Drivers

• Increased prevalence of glaucoma: ~60 million individuals affected globally (WHO, 2020).
• Improved diagnostic capabilities.
• Strategic alliances to expand in emerging markets.

Cost Considerations

• R&D expenses: Approximately 10–15% of sales.
• Manufacturing investments for biosimilars/better formulations.
• Marketing and distribution costs, especially in low-income regions.

---

Market Challenges and Risks

Risk Factors	Impacts	Mitigation Strategies
Patent expiries	Price reduction, revenue loss	Innovate with formulation improvements, broaden pipeline
Regulatory hurdles	Delays, increased costs	Engage early with agencies, leverage fast-track options
Competition from generics/biosimilars	Margins shrinkage	Focus on brand differentiation and patient adherence
Supply chain disruptions	Stock shortages	Diversify manufacturing sites, develop local partnerships

---

Comparison of Investment Opportunities

Criterion	Brimonidine Tartrate	Brinzolamide	Comments
Market Growth	Moderate	Slightly higher	Brinzolamide growing faster due to combination options
Patent Expiry Risk	Moderate	Moderate	Both face patent cliffs over next 2–3 years
Competitive Landscape	Intense	Intense	Mature markets crowded, opportunities via pipeline and biosimilars
Regulatory Barriers	Moderate	Moderate	Both drugs well-established, easier pathways for generics
Revenue Stability	Moderate	Moderate	Stable but susceptible to price erosion

---

Comparative Summary Table

Parameter	Brimonidine Tartrate	Brinzolamide	Remarks
Market Size (2022)	$800 million	$600 million	Both are significant glaucoma drugs
Growth Rate (2023–2030)	3–4%	4–5%	Slightly faster for Brinzolamide
Patent Expiry	2023–2025	202x	Close, increasing generic competition
Major Sales Regions	North America, Europe, Asia-Pacific	Same	Focused on developed markets with expanding emerging markets
Pipeline Status	Incremental improvements, generics	Combination formulations, biosimilars	Higher innovation potential in future

---

Conclusion

Investment prospects for Brimonidine Tartrate and Brinzolamide hinge on patent expiries, competitive pressures, and emerging markets. Both drugs enjoy entrenched market positions with stable revenue streams but face near-term challenges from generics. Strategic focus should be on pipeline innovation, formulation improvements, and geographical expansion. Market growth remains steady, driven by aging populations and increasing glaucoma prevalence.

---

Key Takeaways

• Both drugs have mature markets with predictable growth trajectories, suitable for medium to long-term investment.
• Patent expiries over the next 1–3 years will trigger increased generic competition, impacting gross margins.
• Strategic development of fixed-dose combinations and biosimilars can mitigate patent cliffs.
• The burgeoning prevalence of glaucoma, especially in Asia-Pacific, offers growth opportunities in emerging markets.
• Regulatory and manufacturing challenges require proactive management to sustain market share.

---

FAQs

Q1: How will patent expiries affect the profitability of Brimonidine Tartrate and Brinzolamide?
A: Patent expiries in 2023–2025 are likely to lead to the entry of generics, significantly reducing prices and gross margins. Companies must innovate through formulations, combinations, or pipeline expansion to maintain profitability.

Q2: Are fixed-dose combinations (FDCs) impacting the market share of these drugs?
A: Yes, FDCs combining Brimonidine and Brinzolamide with other agents improve adherence and efficacy, boosting market share and offering new revenue streams.

Q3: Which regions offer the highest growth potential for these drugs?
A: Emerging markets in Asia-Pacific and Latin America present significant growth due to increasing glaucoma prevalence and expanding healthcare infrastructure.

Q4: What regulatory challenges are associated with these drugs?
A: Both drugs face standard regulatory pathways, but biosimilar and generic approvals require extensive comparative data, potentially delaying market entry.

Q5: How does the competitive landscape influence future returns?
A: Intensified competition from generics and biosimilars may compress margins, emphasizing the need for innovation and strategic alliances.

---

References

1. Transparency Market Research. (2022). Ophthalmic Drugs Market Report.
2. World Health Organization (WHO). (2020). Global Glaucoma Prevalence.
3. U.S. Food and Drug Administration (FDA). (2022). Drug Approval Processes.
4. European Medicines Agency (EMA). (2022). Regulatory Framework for Ophthalmic Drugs.
5. MarketWatch. (2023). Pharmaceutical Market Trends.